Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
bladder cancer
Biotech
Acrivon stops testing Lilly castoff for ovarian, bladder cancer
Acrivon is halting work on developing its lead drug for ovarian and bladder cancers, instead focusing the Lilly castoff solely on endometrial cancer.
James Waldron
Mar 26, 2025 7:05am
Pfizer's PD-1 prospect hits goal in phase 3 bladder cancer study
Jan 10, 2025 6:45am
Protara shares spike after bladder cancer data drop
Dec 5, 2024 2:30pm
With ph. 1 data, Aura has an eye on early-stage bladder cancer
Oct 17, 2024 4:05pm
J&J stops phase 3 bladder cancer trial after interim review flop
Oct 8, 2024 4:58am
enGene drops cystic fibrosis program to focus on bladder cancer
Jun 14, 2024 8:20am
